Gavin Herbert is winning converts to his latest venture, which is trying to solve Long Covid.The founder of Allergan is ...

AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare provider. FluMist, which is ...

In a world where most companies seem to be cutting jobs, one company is looking to up their ranks by 25%. MedImmune announced today that they are looking to fill more than 800 positions in research ...

BOSTON (MarketWatch) -- Biotech and pharmaceutical stocks were mixed in trading early Monday as shares of MedImmune soared on news the U.K. drugmaker AstraZeneca plans to buy the U.S. biotech firm for ...

MedImmune accepted a $15.6 billion buyout offer from British drug giant AstraZeneca, capping what was described as a ferociously competitive bidding war for the region's most successful biotech ...

Washington’s most-successful biotech company, MedImmune, will break ground today on a $250 million manufacturing plant in Frederick. The expansion, which will increase the Gaithersburg-based firm’s ...

Ann Arbor-based Michigan Medicine is partnering with MedImmune, the global biologics research and development subsidiary of AstraZeneca, on a three-year research alliance to develop innovative ...

Research commercialization has taken on new importance for universities competing for faculty, students and funding. © 2025 American City Business Journals. All ...

KineMed Inc. announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion ...

WASHINGTON (Reuters) - A newer version of MedImmune Inc.'s FluMist appears effective for children younger than 5 years old, although safety data on the influenza vaccine is still under review, U.S.